News

The research collaboration and license agreement between the partners pertains to the discovery and development of GalXC RNAi therapeutics, with an initial focus on NASH. A chronic liver

Anoro Ellipta is a combination of two bronchodilators in a single dry powder inhaler, the Ellipta. It includes umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI),

Kymriah is a novel immunocellular therapy and a one-time treaent that uses a patient's own T cells to fight cancer. The submission is based on results from the

RBP-6000 is an investigational once-monthly injectable buprenorphine formulation in the ATRIGEL delivery system for the treatment of adults with moderate-to-severe OUD, as part of a complete treatment plan

The objective of the Elaris EM­III and Elaris EM­IV extension studies was to assess the long-term safety and efficacy of elagolix for the management of endometriosis with associated pain..

In 1984, the partnership had formed Kirin-Amgen to fund the global development of Epogen (epoetin alfa). Later, Kirin-Amgen also involved in the development of Neupogen, Neulasta (pegfilgrastim), Aranesp

The merger will result in a combined company, Vaxart, Inc., focused on developing orally-delivered therapeutics and prophylactics to address a variety of viral infections. “We are thrilled with

Under Voyager’s Collaboration Agreement with Sanofi Genzyme, Sanofi Genzyme had an exclusive option for ex-U.S. development and commercial rights to VY-AADC. Based on Voyager’s understanding that because this

MCL represents 3% to 10% of all non-Hodgkin lymphoma cases in the US, as per the National Cancer Institute at the National Institutes of Health. Calquence functions by